Although IL‐6 is involved in stimulating CRP production from hepatocytes,7 reduction of CRP levels from baseline to week 12 does not appear to differ by any clinically meaningful extent for these JAK inhibitors when used to treat RA: tofacitinib 5 mg BID (−10.1 mg/L23); baricitinib 4 mg QD (approximately −10 mg/L24); upadacitinib 6 mg BID (−8.8 mg/L25); and filgotinib 200 mg QD (−14.9 mg/L26). This evidence concerns the gene IL6 and rheumatoid arthritis.